Abstract
Peptides exist in solution as an equilibrium mixture of conformers. The backbone conformational constraints are of interest as a means of limiting degrees of freedom and thereby constraining a synthetic peptide into the bioactive conformation. This concept plays an important role in the design of peptidomimetics in the drug development process. In the early eighties, Freidinger proposed the concept of protected lactam-bridged dipeptides, which was a milestone in the design of conformationally constrained peptides. These types of compounds, now widely known as Freidinger lactams, have been of interest to many medicinal and peptide chemists. This review seeks to present the various applications that Freidinger lactams and their hetero-, fused- and unsaturated analogs have found in the design of conformationally constrained peptidomimetics in different therapeutic areas.
Keywords: Freidinger lactams, dipeptide mimetics, lactam peptidomimetics, conformationally constrained peptide analogs, peptidomimetic design
Current Medicinal Chemistry
Title: The Application of Freidinger Lactams and their Analogs in the Design of Conformationally Constrained Peptidomimetics
Volume: 13 Issue: 13
Author(s): Andrej Perdih and Danijel Kikelj
Affiliation:
Keywords: Freidinger lactams, dipeptide mimetics, lactam peptidomimetics, conformationally constrained peptide analogs, peptidomimetic design
Abstract: Peptides exist in solution as an equilibrium mixture of conformers. The backbone conformational constraints are of interest as a means of limiting degrees of freedom and thereby constraining a synthetic peptide into the bioactive conformation. This concept plays an important role in the design of peptidomimetics in the drug development process. In the early eighties, Freidinger proposed the concept of protected lactam-bridged dipeptides, which was a milestone in the design of conformationally constrained peptides. These types of compounds, now widely known as Freidinger lactams, have been of interest to many medicinal and peptide chemists. This review seeks to present the various applications that Freidinger lactams and their hetero-, fused- and unsaturated analogs have found in the design of conformationally constrained peptidomimetics in different therapeutic areas.
Export Options
About this article
Cite this article as:
Perdih Andrej and Kikelj Danijel, The Application of Freidinger Lactams and their Analogs in the Design of Conformationally Constrained Peptidomimetics, Current Medicinal Chemistry 2006; 13 (13) . https://dx.doi.org/10.2174/092986706777442066
DOI https://dx.doi.org/10.2174/092986706777442066 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents Melatonin and Melatonergic Influence on Neuronal Transcription Factors: Implications for the Development of Novel Therapies for Neurodegenerative Disorders
Current Neuropharmacology Modulation of Endoplasmic Reticulum Stress: An Opportunity to Prevent Neurodegeneration?
CNS & Neurological Disorders - Drug Targets The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems
Current Drug Targets Excitotoxicity as a Target Against Neurodegenerative Processes
Current Pharmaceutical Design Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Current Alzheimer Research Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Parkinson's Disease: A Role for the Immune System
Current Molecular Pharmacology Targeting Neurotrophin Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology The Molecular Basis of Memantine Action in Alzheimers Disease and Other Neurologic Disorders: Low-affinity, Uncompetitive Antagonism
Current Alzheimer Research Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design
Current Neuropharmacology Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis
Current Alzheimer Research Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Neuroprotective Potential of Adenyl Cyclase/cAMP/CREB and Mitochondrial CoQ10 Activator in Amyotrophic Lateral Sclerosis Rats
Current Bioactive Compounds Can Trehalose Prevent Neurodegeneration? Insights from Experimental Studies
Current Drug Targets Parkinson's Disease: From Genetics to Clinical Practice
Current Genomics The Involvement of Post-Translational Modifications in Alzheimer's Disease
Current Alzheimer Research